Literature DB >> 94628

Effects of labetalol on plasma renin, aldosterone, and catecholamines in hypertensive patients.

P J Lijnen, A K Amery, R H Fagard, T M Reybrouck, E J Moerman, A F De Schaepdryver.   

Abstract

We studied the effects of labetalol, an alpha- and beta-adrenoceptor antagonist, on maximum exercise heart rate and on plasma renin, aldosterone, noradrenaline, and adrenaline levels at rest and during exercise in hypertensive patients. The dose of labetalol was doubled weekly from 0.3 to 2.4 g per day. The maximum exercise heart rate fell significantly during labetalol treatment, and there was a significant correlation between exercise tachycardia and the dosage of labetalol. Plasma renin activity and aldosterone concentration at rest decreased during treatment with labetalol. The exercise-induced increase in plasma renin activity was reduced by labetalol. Labetalol did not cause any significant changes in plasma noradrenaline and adrenaline at rest or during exercise.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94628     DOI: 10.1097/00005344-197911000-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Nadolol and labetalol: comparative efficacy of two beta-blocking agents in glaucoma.

Authors:  G K Krieglstein; D Kontić
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981

Review 2.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 3.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 4.  Alpha- and beta-blockade in angina pectoris.

Authors:  S H Taylor
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 5.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.